Editas' gene editing technique at center of patent dispute
Send this to a friend
- Don Seiffert
- BioFlash Editor- Boston Business Journal
- Email | Twitter
The rights to a ground-breaking technique of manipulating DNA known by the cryptic name of CRISPR-Cas9 — the basis of local biotech Editas Medicine — is at the center of a bitter patent dispute that could be worth billions in coming years.
In a report this week, MIT Technology Review detailed the battle between biologists Jennifer Doudna and Emmanuelle Charpentier, who have filed for a patent held by Swiss biotech CRISPR Therapeutics, and Feng Zhang of the Broad Institute, scientific founder of Editas in Cambridge.
The story is complicated to say the least, with Charpentier having co-founded CRISPR Therapeutics based on one patent application for the technique, and Zhang's Editas having received a patent award in April based on a separate application. Doudna, the article states, helped found Editas, but is now no longer connected with the company, and reportedly sold the rights to her patent to CRISPR Therapeutics.
The technique involves using genetic engineering for what's described as a "search and replace function" for DNA, changing the function of genes or making them inactive.
Editas earlier this week announced it is licensing the technology to the Broad Institute, Duke University and Massachusetts General Hospital.
Most Popular
- Most viewed
- Most Emailed
- Harvard students help rebuild Afghanistan with one ingredient: Saffron
- Two big problems facing rare disease biotechs that no one talks about
- In wake of cancer drug rejection, Aveo Oncology plots a comeback
- CookRadar wants to connect foodies with chefs in their neighborhood
- Guest commentary: Five tech predictions for 2015
- Carbonite names former HP exec Mohamad Ali as CEO
Mass High Tech Twitter
-
MassHighTechMass High Tech
Sanjing Pharma Says Chairman Jumps to Death During Probe http://t.co/yjmlMm1iog via @BloombergNews
20 May
Email Newsletter Signup
Choose newsletter(s) you would like to receive.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.